Allogene Therapeutics (ALLO) Invested Capital (2019 - 2025)
Historic Invested Capital for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $315.3 million.
- Allogene Therapeutics' Invested Capital fell 3200.42% to $315.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $315.3 million, marking a year-over-year decrease of 3200.42%. This contributed to the annual value of $422.2 million for FY2024, which is 1758.07% down from last year.
- Latest data reveals that Allogene Therapeutics reported Invested Capital of $315.3 million as of Q3 2025, which was down 3200.42% from $344.6 million recorded in Q2 2025.
- Over the past 5 years, Allogene Therapeutics' Invested Capital peaked at $1.1 billion during Q1 2021, and registered a low of $315.3 million during Q3 2025.
- Its 5-year average for Invested Capital is $646.6 million, with a median of $592.0 million in 2023.
- Its Invested Capital has fluctuated over the past 5 years, first soared by 7638.01% in 2021, then plummeted by 3309.99% in 2025.
- Quarter analysis of 5 years shows Allogene Therapeutics' Invested Capital stood at $925.2 million in 2021, then fell by 27.92% to $666.9 million in 2022, then fell by 23.19% to $512.2 million in 2023, then dropped by 17.58% to $422.2 million in 2024, then decreased by 25.31% to $315.3 million in 2025.
- Its last three reported values are $315.3 million in Q3 2025, $344.6 million for Q2 2025, and $385.4 million during Q1 2025.